HEMGENIX® On Hold

CSL Behring has notified the hemophilia B community of a temporary global stockout of Hemgenix. This situation is not related to the safety or effectiveness of Hemgenix, but reflects the inherent complexity of manufacturing gene therapies and CSL Behring’s unwavering commitment to the highest regulatory and quality standards. Importantly, CSL Behring has provided a formal commitment letter confirming their dedication to resuming full production and ensuring continued access to this therapy.Read the letter here.

LA Kelley Communications, Inc., Communique, April 2026